|
시장보고서
상품코드
1859994
세계의 무혈청 동결 배지 : 시장 점유율과 순위, 전체 매출 및 수요 예측(2025-2031년)Serum-Free Freezing Media - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 무혈청 동결 배지 시장 규모는 2024년에 2억 4,300만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 8.1%로 성장하여 2031년까지 4억 600만 달러로 확대될 것으로 예측됩니다.
본 보고서는 최근 무혈청 동결 배지에 대한 관세 조정과 국제적인 전략적 대응 조치에 대해 국경 간 산업 발자국, 자본 배분 패턴, 지역 경제의 상호 의존성, 공급망 재구축 등의 관점에서 종합적인 평가를 제공합니다.
무혈청 동결 배지란 동물 유래 혈청(태아 소 혈청 등)을 사용하지 않고 세포나 조직을 장기 동결보존하기 위해 고안된 특수한 동결보존 배지를 말합니다. 이러한 배지는 화학적으로 정의된 성분, 재조합 또는 식물 유래 대체물, 합성 동결 보호제(예: DMSO 및 대체 동결 보호제), 완충 시스템, 삼투압 조절제, 필수 영양소에 의존합니다. 그 목적은 저장, 운송 또는 다운스트림 공정의 해동 및 배양 및 응용 과정에서 초저온(종종 -80℃에서 액체 질소까지)에서 세포의 생존율, 형태 및 기능적 무결성을 유지하는 것입니다. 혈청 함유 시스템에 비해 무혈청 동결 배지는 배치 간 일관성이 높고, 동물 유래 성분의 오염 및 병원체 전파 위험이 낮으며, 윤리적 및 규제 기준에 대한 적합성이 우수하고, 연구 및 산업 바이오 생산 환경 모두에서 재현성이 향상됩니다. 2024년 세계 무혈청 동결 배지 생산량은 약 166천 리터에 달했고, 세계 평균 시장가격은 리터당 약 1460달러였습니다.
바이오의약품 연구, 세포 및 유전자 치료, 재생의료가 전 세계적으로 빠르게 발전하고 있는 가운데, 무혈청 동결 배지는 시장 확대의 강력한 단계에 있습니다. 첫째, 많은 국가의 규제 체계가 동물 유래 재료와 관련된 위험(병원체, 교차 오염, 윤리적 문제)에 대한 요구 사항을 강화하고 있으며, 업계는 무혈청 시스템으로 전환해야 하는 상황에 처해 있습니다. 둘째, 학술 기관과 산업 사용자 모두 반복성과 배치 간 일관성을 중요시하는 가운데, 무혈청 시스템은 혈청 유래의 변동 요인을 줄이고 해동 후 세포 생존율, 형태 및 기능적 무결성을 향상시킵니다. 셋째, 전 세계적으로 세포 기반 치료제/백신 개발 파이프라인 수와 투자 금액이 증가하고 있으며, 이러한 용도로는 안전성, 안정성, 보존/수송 성능이 우수한 동결보존 배지가 요구되고 있습니다. 넷째, 신흥시장(특히 중국, 인도, 기타 아시아태평양 국가)의 생명공학 기반, 연구개발 투자, 정책지원이 빠르게 강화되고 있어 무혈청 동결 배지의 현지 생산과 시장 침투에 큰 기회를 창출하고 있습니다. 한편, 업계 내 기술 혁신은 가속화되고 있습니다. 일부 기업들은 연례 보고서에서 주요 원료와 동결 방지제의 자체 개발을 달성하고 기초 연구부터 상업 생산까지 아우르는 통합 플랫폼을 구축하여 비용 절감과 대응력을 향상시켰다고 보고하고 있습니다(출처: 기업 연례 보고서).
이러한 큰 기회가 있는 반면, 심각한 도전도 존재합니다. 첫째, 무혈청 동결 배지는 배합의 복잡성이 높고, 고품질, 고순도 원료와 엄격한 제조 공정(무균, 콜드체인, 동결 해동 손상 제어 등)을 필요로하는 경향이 있으며, 이 모든 것이 생산 비용을 높이고 특히 중소 제조업체의 이익률을 낮추는 경향이 있습니다. 둘째, 세포종 특이성입니다. 다양한 세포주(줄기세포, 유전자 편집 세포주, 고밀도 생산 세포주 등)는 각각 고유한 요구사항을 가지고 있습니다. 범용 무혈청 동결 배지에서는 모든 세포종에서 최적의 생존율과 기능성을 얻지 못할 수 있으며, 장기간의 연구개발 주기와 성능 검증이 필요합니다. 셋째, 규제 및 컴플라이언스 리스크입니다. 예를 들어, 안전성 증명, 동물성 성분 무함유 증명, 밸리데이션 실시, 배치 간 일관성, 생체적합성 등 모두 시간과 리소스가 소요됩니다. 넷째, 경쟁 리스크: 써모피셔, 머크 등 기존 세계 기업들은 강력한 브랜드 파워, 규모, 유통망을 보유하고 있습니다. 신규 진입 기업이나 지역 기업의 경우, 브랜드 신뢰도와 품질 평가를 구축하는 데는 많은 비용과 시간이 소요됩니다. 또한, 지적재산권 침해 및 유출 위험, 또는 다운스트림 고객의 니즈 변화로 인한 처방의 진부화 위험도 존재합니다.
다운스트림 수요는 기초 조사에서 다양화, 전문화되는 추세입니다. 학술기관은 여전히 중요한 수요처로, 세포생물학, 발생생물학, 면역학, 줄기세포 연구를 지원하기 위해 동결 후 생존율, 형태, 유전자 발현 등을 안정적으로 유지하는 동결배지를 선호합니다. 제약/바이오 기업은 비임상, 임상, 상업화 단계에 걸쳐 GMP 또는 이와 동등한 규제 기준을 충족하고 보관 및 운송 중에 우수한 성능을 발휘하는 냉동 배지를 필요로 합니다. CDMO/CRO 서비스 제공업체는 주요 중간 사용자가 되고 있으며, 많은 고객을 지원하기 위해 광범위한 적용성과 일관된 품질, 우수한 고객 지원을 갖춘 제품을 필요로 합니다. 또한, 재생의료, 조직공학, 세포농업, 대체육 등 신흥 다운스트림 분야에서는 더욱 엄격한 요구사항이 요구되고 있습니다. 특히, 높은 회수율, 낮은 독성, 동물성 성분 무함유, 높은 배치 간 일관성, 그리고 비용 효율성입니다. 지역별로 보면 성숙 시장(북미, 유럽)의 다운스트림 수요는 컴플라이언스와 고성능을 중시하고 있습니다. 반면, 아시아태평양(특히 중국)은 빠른 성장세를 보이고 있지만, 가격 민감도와 현지 공급이 중요한 요소로 작용하고 있습니다. 중국 기업(예: 이교신주)은 자사의 무혈청 배지가 이미 HEK-293 세포, 곤충세포 등 다양한 세포종에 대응할 수 있다고 보고하고 있어 수요의 세포종 다변화를 보여주고 있습니다.
무혈청 동결 배지의 원료에는 동결 보호제(예: 디메틸 설폭사이드, 글리세롤, 프로필렌 글리콜, 또는 새로운 저독성 대안), 영양 성분(아미노산, 비타민, 무기염, 완충염), 삼투압 조절제(동결/해동 시 삼투압 스트레스 관리), 재조합 단백질 또는 성장인자, 멸균수, 안정제, 적절한 완충제 등이 포함될 수 있습니다. 또는 식물 유래/합성 대체품, 멸균수, 안정제, 적절한 완충제 등을 들 수 있습니다. 그 중에서도 DMSO 또는 이에 상응하는 보호제가 여전히 주류입니다. 많은 배지가 여전히 DMSO를 함유하고 있기 때문입니다. 비 DMSO 대체품에 대한 관심이 높아지고 있지만, 성능이나 시장 점유율에서 DMSO를 완전히 대체하지는 못하고 있습니다. 고순도 아미노산, 성장인자 또는 재조합 단백질은 고가이고 공급업체가 한정되어 있기 때문에 업스트림 공급업체가 우위에 있으며, 품질, 인증(예: GMP 또는 이에 준하는 인증) 및 공급 안정성이 주요 위험 요소입니다. 순도와 균일성은 매우 중요합니다. 배치/로트 단위의 불순물이나 오염(화학적, 미생물학적)은 해동 후 생존율을 극적으로 감소시키거나 기능적 거동을 변화시킬 수 있습니다. 또한, 세계 수요 증가(특히 급성장 시장)에 따라 인증된 고순도 재료의 가용성, 물류(콜드체인 및 운송), 수출입 정책, 관세 등이 비용과 리드타임에 영향을 미칩니다. 일부 기업(특히 중국 기업)은 연차보고서에서 해외 공급업체 의존도 감소, 비용 관리, 공급망 리스크 감소를 위해 주요 원자재 및 부품의 개발 또는 자체 생산을 진행하고 있음을 명시하고 있습니다.
이 보고서는 무혈청 동결 배지 세계 시장에 대해 총 판매량, 매출, 매출액, 가격, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목표로 합니다.
이 보고서는 2024년을 기준 연도, 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하여 판매량(천 리터)과 매출액(백만 달러)으로 무혈청 동결 배지 시장 규모를 추정 및 예측하고 있습니다. 정량적, 정성적 분석을 통해 독자들이 비즈니스/성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, 무혈청 동결 배지 관련 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 도와드립니다.
시장 세분화
기업별
- Thermo Fisher
- Merck
- Zenoaq
- STEMCELL
- Cytiva
- BioLifeSolutions
- Fujifilm
- Lonza
- Sartorius
- Nippon Genetics
- HiMedia
- PromoCell
유형별 부문
- DMSO 함유
- DMSO 프리
용도별 부문
- 학술·연구기관
- 제약·바이오테크놀러지 기업
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Serum-Free Freezing Media was estimated to be worth US$ 243 million in 2024 and is forecast to a readjusted size of US$ 406 million by 2031 with a CAGR of 8.1% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Serum-Free Freezing Media cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Serum-Free Freezing Media refers to specialized cryopreservation media designed for long-term freezing storage of cells or tissues without using animal-derived sera (such as fetal bovine serum). Instead, these media rely on chemically defined components, recombinant or plant-derived substitutes, or synthetic cryoprotectants (e.g., DMSO or alternative cryoprotectants), buffering systems, osmotic regulators, and essential nutrients. Its purpose is to maintain cell viability, morphology, and functional integrity under ultra-low temperatures (often -80 °C down to liquid nitrogen) for storage, transport, or downstream thawing and culture/applications. Compared to serum-containing systems, serum-free freezing media offer higher batch-to-batch consistency, lower risk of animal component contamination or pathogen transmission, better alignment with ethical/regulatory standards, and improved reproducibility in both research and industrial bioproduction settings.In 2024, global Serum-Free Freezing Media production reached approximately 166 k L, with an average global market price of around US$ 1460 per L.
Against the backdrop of rapid advances in biopharmaceutical research, cell & gene therapies, and regenerative medicine globally, serum-free freezing media is at a phase of strong market expansion. First, regulatory regimes in many countries are strengthening requirements around risks associated with animal-derived materials (pathogens, cross-contamination, ethical concerns), pushing the industry to shift from serum-containing to serum-free systems. Second, both academic and industrial users are emphasizing reproducibility and batch-to-batch consistency; serum-free systems offer reduced variability introduced by serum, improving post-thaw cell viability, morphology, and functional integrity. Third, the number and investment volume of cell-based therapy/vaccine pipelines are rising worldwide; these applications demand freezing media with high safety, stability, and storage/transport performance. Fourth, emerging markets-especially in China, India, and other Asia-Pacific countries-are rapidly enhancing biotech infrastructure, R&D investment, and policy support, creating large opportunity for local manufacture and market penetration of serum-free freezing media. Meanwhile, technological innovation inside the industry is accelerating: some companies report in their annual reports that they have achieved in-house development of key raw materials or cryoprotectants and built integrated platforms spanning from basic research to commercial production, which helps lower costs and improve responsiveness. (Sources: enterprise annual reports).
Despite the strong opportunities, there are significant challenges. First, serum-free freezing media tend to have higher formulation complexity and require higher quality/purity of raw materials and stricter manufacturing processes (sterility, cold chain, control of freeze-thaw damage etc.), which all increase production cost and reduce margin, particularly for smaller manufacturers. Second, cell-type specificity: various cell lines (stem cells, gene-edited lines, high density production cell lines) each have unique requirements; a generic serum-free freezing medium may not give optimum viability/function across all, meaning long R&D cycles and performance validation are needed. Third, regulatory and compliance risks: for example, proving safety, proving residual animal-component absence, performing validation, batch consistency, biocompatibility, all take time and resources. Fourth, competitive risk: established global players like Thermo Fisher, Merck etc. have strong brand, scale, distribution; for new entrants or local firms, building brand trust, quality reputation is expensive and time consuming. There is also risk of IP infringement or leakage, or formula becoming obsolete if downstream customer needs change.
Downstream demand is trending from basic research toward greater diversity and specialization. Academic institutions remain important demand centers, prioritizing freezing media that deliver stable post-thaw viability, morphology, gene expression etc., to support cell biology, developmental biology, immunology, stem cell research. Pharma / biotech companies require freezing media that meet GMP or comparable regulatory standards across preclinical, clinical, commercial phases, and that perform well during storage/transport. CDMO / CRO service providers are becoming key mid-users, supporting many clients and needing broadly applicable, consistent quality products along with good customer support. Also, emerging downstream sectors-regenerative medicine, tissue engineering, cellular agriculture, alternative meats, etc.-are starting to specify more stringent requirements: high recovery rate, low toxicity, no animal-origin components, high batch consistency, and cost-effectiveness. Geographically, downstream demand in mature markets (North America, Europe) emphasizes compliance, premium performance; in Asia-Pacific (especially China), the growth is rapid, but price sensitivity and local supply are important factors. Chinese firms (e.g. Yiqiao Shenzhou) report that their serum-free media already cover cell types like HEK-293, insect cells etc., showing cell-type diversification of demand.
The upstream raw materials for serum-free freezing media include: cryoprotectants (e.g. DMSO, glycerol, propylene glycol or newer lower toxicity alternatives), nutritional components (amino acids, vitamins, inorganic salts, buffering salts), osmotic regulators (to manage osmotic stress during freeze/thaw), recombinant proteins or growth factors or plant/synthetic substitutes, sterile water, stabilizers and appropriate buffering agents. Among these, DMSO or equivalent protectants remain dominant because many media still include DMSO; though non-DMSO alternatives are gaining interest, they have not yet fully displaced DMSO in performance or market share. High purity amino acids, growth factors or recombinant proteins are expensive and often supplied by few vendors, giving upstream suppliers leverage and making quality, certification (e.g. GMP or equivalent), and supply stability key risks. Purity and consistency are absolutely crucial: any batch/lot impurity or contamination (chemical, microbial) can dramatically reduce post-thaw viability or alter functional behavior. Also, as demand rises globally (especially in fast-growing markets), availability of certified high-purity material, logistics (cold chain, transport), import/export policies, tariffs etc. affect cost and lead time. Some companies (notably in China) in their annual reports explicitly state that they are developing or internally producing key raw materials / componentsto reduce dependence on foreign suppliers, control cost and reduce supply chain risk.
This report aims to provide a comprehensive presentation of the global market for Serum-Free Freezing Media, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Serum-Free Freezing Media by region & country, by Type, and by Application.
The Serum-Free Freezing Media market size, estimations, and forecasts are provided in terms of sales volume (K Liters) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Serum-Free Freezing Media.
Market Segmentation
By Company
- Thermo Fisher
- Merck
- Zenoaq
- STEMCELL
- Cytiva
- BioLifeSolutions
- Fujifilm
- Lonza
- Sartorius
- Nippon Genetics
- HiMedia
- PromoCell
Segment by Type
- With DMSO
- DMSO-free
Segment by Application
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Serum-Free Freezing Media manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Serum-Free Freezing Media in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Serum-Free Freezing Media in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Serum-Free Freezing Media Product Introduction
- 1.2 Global Serum-Free Freezing Media Market Size Forecast
- 1.2.1 Global Serum-Free Freezing Media Sales Value (2020-2031)
- 1.2.2 Global Serum-Free Freezing Media Sales Volume (2020-2031)
- 1.2.3 Global Serum-Free Freezing Media Sales Price (2020-2031)
- 1.3 Serum-Free Freezing Media Market Trends & Drivers
- 1.3.1 Serum-Free Freezing Media Industry Trends
- 1.3.2 Serum-Free Freezing Media Market Drivers & Opportunity
- 1.3.3 Serum-Free Freezing Media Market Challenges
- 1.3.4 Serum-Free Freezing Media Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Serum-Free Freezing Media Players Revenue Ranking (2024)
- 2.2 Global Serum-Free Freezing Media Revenue by Company (2020-2025)
- 2.3 Global Serum-Free Freezing Media Players Sales Volume Ranking (2024)
- 2.4 Global Serum-Free Freezing Media Sales Volume by Company Players (2020-2025)
- 2.5 Global Serum-Free Freezing Media Average Price by Company (2020-2025)
- 2.6 Key Manufacturers Serum-Free Freezing Media Manufacturing Base and Headquarters
- 2.7 Key Manufacturers Serum-Free Freezing Media Product Offered
- 2.8 Key Manufacturers Time to Begin Mass Production of Serum-Free Freezing Media
- 2.9 Serum-Free Freezing Media Market Competitive Analysis
- 2.9.1 Serum-Free Freezing Media Market Concentration Rate (2020-2025)
- 2.9.2 Global 5 and 10 Largest Manufacturers by Serum-Free Freezing Media Revenue in 2024
- 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Serum-Free Freezing Media as of 2024)
- 2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 With DMSO
- 3.1.2 DMSO-free
- 3.2 Global Serum-Free Freezing Media Sales Value by Type
- 3.2.1 Global Serum-Free Freezing Media Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Serum-Free Freezing Media Sales Value, by Type (2020-2031)
- 3.2.3 Global Serum-Free Freezing Media Sales Value, by Type (%) (2020-2031)
- 3.3 Global Serum-Free Freezing Media Sales Volume by Type
- 3.3.1 Global Serum-Free Freezing Media Sales Volume by Type (2020 VS 2024 VS 2031)
- 3.3.2 Global Serum-Free Freezing Media Sales Volume, by Type (2020-2031)
- 3.3.3 Global Serum-Free Freezing Media Sales Volume, by Type (%) (2020-2031)
- 3.4 Global Serum-Free Freezing Media Average Price by Type (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Academic & Research Institutes
- 4.1.2 Pharmaceutical & Biotechnology Companies
- 4.2 Global Serum-Free Freezing Media Sales Value by Application
- 4.2.1 Global Serum-Free Freezing Media Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Serum-Free Freezing Media Sales Value, by Application (2020-2031)
- 4.2.3 Global Serum-Free Freezing Media Sales Value, by Application (%) (2020-2031)
- 4.3 Global Serum-Free Freezing Media Sales Volume by Application
- 4.3.1 Global Serum-Free Freezing Media Sales Volume by Application (2020 VS 2024 VS 2031)
- 4.3.2 Global Serum-Free Freezing Media Sales Volume, by Application (2020-2031)
- 4.3.3 Global Serum-Free Freezing Media Sales Volume, by Application (%) (2020-2031)
- 4.4 Global Serum-Free Freezing Media Average Price by Application (2020-2031)
5 Segmentation by Region
- 5.1 Global Serum-Free Freezing Media Sales Value by Region
- 5.1.1 Global Serum-Free Freezing Media Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Serum-Free Freezing Media Sales Value by Region (2020-2025)
- 5.1.3 Global Serum-Free Freezing Media Sales Value by Region (2026-2031)
- 5.1.4 Global Serum-Free Freezing Media Sales Value by Region (%), (2020-2031)
- 5.2 Global Serum-Free Freezing Media Sales Volume by Region
- 5.2.1 Global Serum-Free Freezing Media Sales Volume by Region: 2020 VS 2024 VS 2031
- 5.2.2 Global Serum-Free Freezing Media Sales Volume by Region (2020-2025)
- 5.2.3 Global Serum-Free Freezing Media Sales Volume by Region (2026-2031)
- 5.2.4 Global Serum-Free Freezing Media Sales Volume by Region (%), (2020-2031)
- 5.3 Global Serum-Free Freezing Media Average Price by Region (2020-2031)
- 5.4 North America
- 5.4.1 North America Serum-Free Freezing Media Sales Value, 2020-2031
- 5.4.2 North America Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
- 5.5 Europe
- 5.5.1 Europe Serum-Free Freezing Media Sales Value, 2020-2031
- 5.5.2 Europe Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
- 5.6 Asia Pacific
- 5.6.1 Asia Pacific Serum-Free Freezing Media Sales Value, 2020-2031
- 5.6.2 Asia Pacific Serum-Free Freezing Media Sales Value by Region (%), 2024 VS 2031
- 5.7 South America
- 5.7.1 South America Serum-Free Freezing Media Sales Value, 2020-2031
- 5.7.2 South America Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
- 5.8 Middle East & Africa
- 5.8.1 Middle East & Africa Serum-Free Freezing Media Sales Value, 2020-2031
- 5.8.2 Middle East & Africa Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Serum-Free Freezing Media Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Serum-Free Freezing Media Sales Value and Sales Volume
- 6.2.1 Key Countries/Regions Serum-Free Freezing Media Sales Value, 2020-2031
- 6.2.2 Key Countries/Regions Serum-Free Freezing Media Sales Volume, 2020-2031
- 6.3 United States
- 6.3.1 United States Serum-Free Freezing Media Sales Value, 2020-2031
- 6.3.2 United States Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Serum-Free Freezing Media Sales Value, 2020-2031
- 6.4.2 Europe Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Serum-Free Freezing Media Sales Value, 2020-2031
- 6.5.2 China Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Serum-Free Freezing Media Sales Value, 2020-2031
- 6.6.2 Japan Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Serum-Free Freezing Media Sales Value, 2020-2031
- 6.7.2 South Korea Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Serum-Free Freezing Media Sales Value, 2020-2031
- 6.8.2 Southeast Asia Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Serum-Free Freezing Media Sales Value, 2020-2031
- 6.9.2 India Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Thermo Fisher
- 7.1.1 Thermo Fisher Company Information
- 7.1.2 Thermo Fisher Introduction and Business Overview
- 7.1.3 Thermo Fisher Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 Thermo Fisher Serum-Free Freezing Media Product Offerings
- 7.1.5 Thermo Fisher Recent Development
- 7.2 Merck
- 7.2.1 Merck Company Information
- 7.2.2 Merck Introduction and Business Overview
- 7.2.3 Merck Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Merck Serum-Free Freezing Media Product Offerings
- 7.2.5 Merck Recent Development
- 7.3 Zenoaq
- 7.3.1 Zenoaq Company Information
- 7.3.2 Zenoaq Introduction and Business Overview
- 7.3.3 Zenoaq Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Zenoaq Serum-Free Freezing Media Product Offerings
- 7.3.5 Zenoaq Recent Development
- 7.4 STEMCELL
- 7.4.1 STEMCELL Company Information
- 7.4.2 STEMCELL Introduction and Business Overview
- 7.4.3 STEMCELL Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 STEMCELL Serum-Free Freezing Media Product Offerings
- 7.4.5 STEMCELL Recent Development
- 7.5 Cytiva
- 7.5.1 Cytiva Company Information
- 7.5.2 Cytiva Introduction and Business Overview
- 7.5.3 Cytiva Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 Cytiva Serum-Free Freezing Media Product Offerings
- 7.5.5 Cytiva Recent Development
- 7.6 BioLifeSolutions
- 7.6.1 BioLifeSolutions Company Information
- 7.6.2 BioLifeSolutions Introduction and Business Overview
- 7.6.3 BioLifeSolutions Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 BioLifeSolutions Serum-Free Freezing Media Product Offerings
- 7.6.5 BioLifeSolutions Recent Development
- 7.7 Fujifilm
- 7.7.1 Fujifilm Company Information
- 7.7.2 Fujifilm Introduction and Business Overview
- 7.7.3 Fujifilm Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 Fujifilm Serum-Free Freezing Media Product Offerings
- 7.7.5 Fujifilm Recent Development
- 7.8 Lonza
- 7.8.1 Lonza Company Information
- 7.8.2 Lonza Introduction and Business Overview
- 7.8.3 Lonza Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 Lonza Serum-Free Freezing Media Product Offerings
- 7.8.5 Lonza Recent Development
- 7.9 Sartorius
- 7.9.1 Sartorius Company Information
- 7.9.2 Sartorius Introduction and Business Overview
- 7.9.3 Sartorius Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Sartorius Serum-Free Freezing Media Product Offerings
- 7.9.5 Sartorius Recent Development
- 7.10 Nippon Genetics
- 7.10.1 Nippon Genetics Company Information
- 7.10.2 Nippon Genetics Introduction and Business Overview
- 7.10.3 Nippon Genetics Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Nippon Genetics Serum-Free Freezing Media Product Offerings
- 7.10.5 Nippon Genetics Recent Development
- 7.11 HiMedia
- 7.11.1 HiMedia Company Information
- 7.11.2 HiMedia Introduction and Business Overview
- 7.11.3 HiMedia Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.11.4 HiMedia Serum-Free Freezing Media Product Offerings
- 7.11.5 HiMedia Recent Development
- 7.12 PromoCell
- 7.12.1 PromoCell Company Information
- 7.12.2 PromoCell Introduction and Business Overview
- 7.12.3 PromoCell Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.12.4 PromoCell Serum-Free Freezing Media Product Offerings
- 7.12.5 PromoCell Recent Development
8 Industry Chain Analysis
- 8.1 Serum-Free Freezing Media Industrial Chain
- 8.2 Serum-Free Freezing Media Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Serum-Free Freezing Media Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Serum-Free Freezing Media Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
(주말 및 공휴일 제외)
